Q32 Bio Statistics
Share Statistics
Q32 Bio has 12.18M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 12.18M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 1.68K |
| FTD / Avg. Volume | 0.84% |
Short Selling Information
The latest short interest is 686.07K, so 5.63% of the outstanding shares have been sold short.
| Short Interest | 686.07K |
| Short % of Shares Out | 5.63% |
| Short % of Float | 15.06% |
| Short Ratio (days to cover) | 6.98 |
Valuation Ratios
The PE ratio is -0.31 and the forward PE ratio is -8.15.
| PE Ratio | -0.31 |
| Forward PE | -8.15 |
| PS Ratio | 30.41 |
| Forward PS | 22.5 |
| PB Ratio | 0.48 |
| P/FCF Ratio | -0.36 |
| PEG Ratio | n/a |
Enterprise Valuation
Q32 Bio Inc. has an Enterprise Value (EV) of -2.80M.
| EV / Earnings | 0.02 |
| EV / Sales | -2.42 |
| EV / EBITDA | 0.03 |
| EV / EBIT | 0.03 |
| EV / FCF | 0.03 |
Financial Position
The company has a current ratio of 7.25, with a Debt / Equity ratio of 0.02.
| Current Ratio | 7.25 |
| Quick Ratio | 7.25 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 1.77 |
| Cash Flow / Debt | -73.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.55% and return on capital (ROIC) is -160.78%.
| Return on Equity (ROE) | -1.55% |
| Return on Assets (ROA) | -0.37% |
| Return on Capital (ROIC) | -160.78% |
| Revenue Per Employee | 27.52K |
| Profits Per Employee | -2.69M |
| Employee Count | 42 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 25.88M |
| Effective Tax Rate | -0.3 |
Stock Price Statistics
The stock price has increased by -62.58% in the last 52 weeks. The beta is 0, so Q32 Bio 's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | -62.58% |
| 50-Day Moving Average | 37.17 |
| 200-Day Moving Average | 30.85 |
| Relative Strength Index (RSI) | 15.6 |
| Average Volume (20 Days) | 198.56K |
Income Statement
In the last 12 months, Q32 Bio had revenue of $1.16M and earned -$112.96M in profits. Earnings per share was $-35.16.
| Revenue | 1.16M |
| Gross Profit | 578.00K |
| Operating Income | -92.10M |
| Net Income | -112.96M |
| EBITDA | -86.50M |
| EBIT | -92.10M |
| Earnings Per Share (EPS) | -35.16 |
Balance Sheet
The company has $39.27M in cash and $1.32M in debt, giving a net cash position of $37.95M.
| Cash & Cash Equivalents | 39.27M |
| Total Debt | 1.32M |
| Net Cash | 37.95M |
| Retained Earnings | -542.10M |
| Total Assets | 104.54M |
| Working Capital | 79.52M |
Cash Flow
In the last 12 months, operating cash flow was -$96.23M and capital expenditures -$228.00K, giving a free cash flow of -$96.46M.
| Operating Cash Flow | -96.23M |
| Capital Expenditures | -228.00K |
| Free Cash Flow | -96.46M |
| FCF Per Share | -30.02 |
Margins
Gross margin is 50%, with operating and profit margins of -7.97K% and -9.77K%.
| Gross Margin | 50% |
| Operating Margin | -7.97K% |
| Pretax Margin | -7.53K% |
| Profit Margin | -9.77K% |
| EBITDA Margin | -7.48K% |
| EBIT Margin | -7.97K% |
| FCF Margin | -8.34K% |
Dividends & Yields
QTTB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -952.85% |
| FCF Yield | -214.56% |
Analyst Forecast
The average price target for QTTB is $20, which is 442% higher than the current price. The consensus rating is "Hold".
| Price Target | $20 |
| Price Target Difference | 442% |
| Analyst Consensus | Hold |
| Analyst Count | 7 |
Stock Splits
The last stock split was on Mar 26, 2024. It was a backward split with a ratio of 1:18.
| Last Split Date | Mar 26, 2024 |
| Split Type | backward |
| Split Ratio | 1:18 |
Scores
| Altman Z-Score | -3.38 |
| Piotroski F-Score | 1 |